• Mirxes will be included in the Hang Seng Composite Index (HSCI) from 8 September 2025, after latest review by Hang Seng Indexes Company Limited.
• This move is expected to make its shares more attractive to a broader base of investors, including institutional funds and index-tracking ETFs.
• It is anticipated that the company will be eligible for inclusion in the Southbound Stock Connect, further enhancing its trading liquidity by providing access to Mainland China investors.

Singapore, August 23, 2025 – Mirxes, a leading and only public-listed molecular cancer early detection company in Asia Pacific, today announced its inclusion in the Hang Seng Composite Index (HSCI), effective 8 September 2025. This significant milestone elevates the company’s market profile and enhances its strategic position within the Hong Kong and wider Asian capital markets.

Inclusion in the Hang Seng Composite Index is a powerful testament to Mirxes’ strong market position and solid performance since its listing on the Hong Kong Stock Exchange (HKEX) three months ago. The move is expected to significantly increase the company’s visibility and trading liquidity, making its shares more attractive to a broader base of investors, including institutional funds and index-tracking ETFs.

Eligibility for Southbound Stock Connect

Another key advantage of this inclusion is the likely eligibility of Mirxes’ shares for trading through both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect schemes. This critical development opens up the company’s stock to a vast pool of investors in Mainland China, further enhancing its trading liquidity and providing access to a crucial new source of capital to support its long-term growth and innovation pipeline.

Dr. Zhou Lihan, Co-Founder and CEO of Mirxes, said, “Mirxes is proud to be included in the Hang Seng Composite Index just three months after our IPO. This is a powerful testament to the growing recognition of our mission to make life-changing cancer early detection solutions accessible to all. This inclusion validates our strategic choice to list on the HKEX and reinforces our commitment to expanding our global investor footprint. The entire Mirxes team remains focused on scaling commercial access of GASTROClear in broad Asia Pacific markets and accelerating high impact clinical pipelines towards commercialisation.”

This milestone solidifies Mirxes’ position as a leading player in the global biotech sector and underscores its commitment to leveraging its Hong Kong listing to accelerate its mission of making life-changing cancer early detection accessible to all.

24 New Companies Added After Latest Review

Mirxes’ inclusion in HSCI was announced by Hang Seng Indexes Company Limited yesterday as part of its review of the Hang Seng Family of Indexes for the quarter ended 30 June 2025. All changes will be implemented after market close on 5 September 2025 (Friday) and take effect on 8 September 2025 (Monday). 24 new companies will be added to the HSCI, while 22 will be removed, increasing the number of constituents in the HSCI from 502 to 504. There is a total of 2,337 companies listed on the Main Board of the HKEX as of July 2025.

The HSCI, which serves as a key benchmark for the Hong Kong stock market, covers around the top 95% of the total market capitalisation of companies listed on the Main Board. To get on the HSCI, a company must meet a strict set of criteria focused on its size, trading activity, and representation within the broader Hong Kong market. Mirxes will be among the 17 biotech stocks included in the HSCI after this review, out of 76 biotech companies listed on HKEX through the Chapter 18A route since 2018.